摘要
目的探讨复查PET/CT标准摄取值(SUL)评估非小细胞肺癌(NSCLC)不同周期化疗后疗效的价值。方法 NSCLC患者53例,参照PERCIST标准确定靶病灶。化疗2周期后复查的患者30例(A组),化疗4-6周期后复查的患者23例(B组),两组病例各30个靶病灶。以SUL下降50%作为B组靶病灶部分缓解(PMR)的阈值,比较两组靶病灶治疗前后SUL的变化及治疗有效率。结果 B组靶病灶SUL下降百分比高于A组[(50.00±26.96)%vs.(32.00±42.00)%](P<0.05)。B组靶病灶治疗有效率高于A组(80.0%vs.46.7%)(P<0.05);B组复查的靶病灶以SUL下降50%作为PMR标准,两组治疗效果差异无统计学意义(P>0.05)。结论 NSCLC患者应用PERCIST标准评价疗效时,化疗2周期复查时SUL下降30%以上的疗效类似于4-6周期复查时SUL下降50%以上的疗效。
Objective To investigate the role of PET/CT reexamination in the patients with non-small cell lung cancer（NSCLC） underwent chemotherapy for 2 and 4-6 cycles. Methods A total of 60 target lesions was ascertained according to PERCIST criteria in 53 NSCLC patients, who were reexamined by 18F-FDG PET/CT after chemotherapy for 2 cycles（group A, 30 cases with 30 target lesions） and 4-6 cycles（group B, 23 cases with 30 target lesions）. Taking a 50% decrease of standardized uptake value（SUL） as PMR threshold of SUL in group B, the percentage changes of SUL and therapeutic effectiveness rates before and after treatment were compared between two groups. Results The decrease in SUL percentage was higher in group B than that in group AI（50.00± 26.96） % vs. （32.00 ± 42.00） % ] （P〈0. 05 ）. So did the therapeutic effectiveness rate （ 80. 0 % vs. 46.7%） （P〈0. 05）. Taking a 50% decrease of SUL as PMR threshold of SUL in group B, there was no significant difference in therapeutic effectiveness rate between two groups（P〈0. 05）. Conclusion The efficacy evaluated by ≥30% decrease of SUL after 2 cycles of chemotherapy is similar to that evaluated bye50% decrease of SUL after 4-6 cycles of chemotherapy in the patients with NSCLC.
出处
《江苏医药》
CAS
北大核心
2014年第11期1292-1294,共3页
Jiangsu Medical Journal
